BNP (B-Type Natriuretic Peptide) Ratio/ Urinary cGMP (Cyclic Guanosine Monophosphate), Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction
Dr. S. S. Gett
MD (Medicine) Consultant Physician
The study examined the relationship between urinary cyclic guanosine monophosphate (ucGMP) and B-type natriuretic peptide (BNP) ratio and clinical outcomes in patients with heart failure and reduced ejection fraction. Results showed that patients in higher tertiles had a lower risk of primary outcomes. The ucGMP/BNP ratio was higher with sacubitril/valsartan than with enalapril at 1 month and 8 months after randomization. The effect of sacubitril/valsartan on clinical outcomes was not modified by baseline ucGMP/BNP ratio.